NCT01580995View on ClinicalTrials.gov

Herpes Simplex Type 1 Suppression in Hepatitis C

PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

March 31, 2015

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

Valacyclovir

Valacyclovir 500 mg po bid

DRUG

Placebo

Placebo tablet twice daily

Trial Locations (1)

39216

G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS, Jackson

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

VA Office of Research and Development

FED

NCT01580995 - Herpes Simplex Type 1 Suppression in Hepatitis C | Biotech Hunter | Biotech Hunter